Urinary Clinical Trials

450 recruitingLast updated: May 13, 2026

There are 450 actively recruiting urinary clinical trials across 68 countries. Studies span Not Applicable, Phase 2, Phase 4, Phase 3, Phase 1, Early Phase 1. Top locations include Chicago, Illinois, United States, Houston, Texas, United States, St Louis, Missouri, United States. Updated daily from ClinicalTrials.gov.


Urinary Trials at a Glance

450 actively recruiting trials for urinary are listed on ClinicalTrialsFinder across 6 cities in 68 countries. The largest study group is Not Applicable with 208 trials, with the heaviest enrollment activity in Chicago, Houston, and St Louis. Lead sponsors running urinary studies include National Cancer Institute (NCI), Eli Lilly and Company, and Wake Forest University Health Sciences.

Treatments under study

About Urinary Clinical Trials

Looking for clinical trials for Urinary? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Urinary trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Urinary clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 450 trials

Recruiting
Not Applicable

Aquarius Pilot Study to Evaluate the New Axonics Trial System

Overactive Bladder (OAB)Fecal Incontinence (FI)Urinary Urge Incontinence (UUI)+1 more
Axonics, Inc.75 enrolled1 locationNCT07335484
Recruiting
Not Applicable

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

Prostate CancerProstatectomyBenign Prostatic Hyperplasia+3 more
Axonics, Inc.150 enrolled20 locationsNCT06511141
Recruiting
Phase 1

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

Urinary Bladder NeoplasmsNeoplasm MetastasisUreteral Neoplasms
Eli Lilly and Company535 enrolled84 locationsNCT05614739
Recruiting
Not Applicable

PMCF Study of the Axonics SNM System Model 5101 (R20) for the Indication of OAB

Overactive Bladder (OAB)Urinary Urge Incontinence (UUI)Urinary Frequency (UF)
Axonics, Inc.55 enrolled5 locationsNCT06789406
Recruiting

Stone and Laser Therapies Post-Market Study (SALT)

Benign Prostate Hypertrophy(BPH)Ureteral Stones, Kidney StonesCalculi, Urinary+2 more
Boston Scientific Corporation238 enrolled5 locationsNCT06982235
Recruiting
Phase 1

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Triple-Negative Breast CancerEsophageal CancerPancreatic Cancer+11 more
Eli Lilly and Company420 enrolled31 locationsNCT06465069
Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled579 locationsNCT03866382
Recruiting
Not Applicable

Post Approval Effectiveness and Durability Evaluation of the Altaviva™ Tibial Device

Urge Urinary Incontinence
MedtronicNeuro256 enrolled3 locationsNCT07456865
Recruiting
Not Applicable

Effects of Action Observation and Metaphorical Imagery in Pelvic Floor Muscle Training for Geriatric Urinary Incontinence

Urinary Continence
Fenerbahce University40 enrolled1 locationNCT07551674
Recruiting
Phase 1

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer1,006 enrolled159 locationsNCT04389632
Recruiting

Ethicon Pelvic Mesh Post Market Clinical Follow-up Registry

pelvic organ prolapseStress Urinary Incontinence
Ethicon, Inc.1,000 enrolled10 locationsNCT04829175
Recruiting
Phase 2

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Breast CancerOvarian CancerNon-small Cell Lung Cancer+4 more
National Cancer Institute (NCI)285 enrolled1 locationNCT03412877
Recruiting
Phase 3

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 )

Urinary Bladder NeoplasmsUrothelial Cancer
Astellas Pharma Global Development, Inc.390 enrolled1 locationNCT07566156
Recruiting
Phase 2

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Recurrent Mucosal MelanomaMucosal MelanomaAnal Melanoma+14 more
National Cancer Institute (NCI)101 enrolled147 locationsNCT05111574
Recruiting

Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System

Stress Urinary Incontinence
Ethicon, Inc.195 enrolled4 locationsNCT04829357
Recruiting

Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)

Breast CancerLung CancerMelanoma+7 more
University Health Network, Toronto7,000 enrolled1 locationNCT07524114
Recruiting
Phase 4

Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women

NocturiaUrgency Urinary Incontinence
Shachi Tyagi120 enrolled1 locationNCT05604222
Recruiting
Phase 2

Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer

Urinary Bladder Neoplasms
Queen Mary University of London320 enrolled3 locationsNCT06892860
Recruiting
Phase 2

Antibiotic Prophylaxis for Neurogenic Bladder Botox

Neurogenic BladderPost-operative Urinary Tract Infections
University of Alberta160 enrolled1 locationNCT04791579
Recruiting
Not Applicable

BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair (BELIEVE)

Stress Urinary IncontinenceVaginal prolapse
University Hospitals Cleveland Medical Center476 enrolled1 locationNCT06754046